KERX Related Corporate News

Jan 31, 2013 06:53 AM Keryx Biopharma (KERX) Prices 8.23M Offering at $8.49/Share

Jan 28, 2013 07:07 AM Keryx (KERX) Says Zerenex Phase 3 Met Primary, Secondary Endpoints

Jan 7, 2013 08:05 AM Keryx Biopharma (KERX) Partner Filed NDA in Japan for CKD Treatment; Receives $7M Milestone

Jan 3, 2013 08:40 AM Keryx Bio (KERX) Says Taxpayer Relief Act Delays Oral Only ESRD Drugs

May 7, 2012 07:40 AM Aeterna (AEZS), Keryx (KERX) Terminate Perifosine License Agreement in North America

Apr 23, 2012 08:39 AM Keryx (KERX) Reports Positive Top-Line Data from Zerenex Phase 3

Apr 2, 2012 07:06 AM UPDATE: Keryx (KERX) Says KRX-0401 + Xeloda Did Not Meet Primary Endpoint in Phase 3

Dec 13, 2011 08:28 AM Keryx Biopharma (KERX) Reports Strong Phase 2 Data for Perifosine w/ Sorafenib in Certain HL Patients

Oct 13, 2011 09:36 AM Keryx (KERX) Reports Publication of Data from Perifosine Plus Bortezomib, Dexamethasone Phase 1/2

Oct 5, 2011 08:37 AM Aeterna Zentaris (AEZS) Perifosine Phase 2 Data in mCRC Patients Published

Sep 19, 2011 08:43 AM Keryx Biopharm (KERX) Completes Patient Enrollment in Zerenex Phase 3 Long-Term Study

Aug 31, 2011 08:38 AM Aeterna Zentaris (AEZS) Reports Independent DSMB Completes Pre-Specified Interim Analysis of Perifosine Phase 3 X-PECT (KERX)

Jul 18, 2011 01:57 PM FDA Says Keryx (KERX) Promoted Investigational and Unapproved Drug on Co. Website

May 4, 2011 08:57 AM Keryx Biopharma (KERX) Prices 7.02M Common Offering at $4.70/Share

Apr 28, 2011 04:06 PM Keryx Biopharmaceuticals (KERX) Announces Positive Data From Zerenex Short-Term Phase 3 Study

Apr 18, 2011 08:32 AM Keryx (KERX) Japanese Partner Commences Ferric Citrate Phase 3

Apr 5, 2011 08:46 AM Keryx Biopharma (KERX) Presents Data from Two Perifosine Posters

Mar 28, 2011 09:14 AM Keryx Biopharma (KERX) To Update on Perifosine at 102nd AACR

Dec 6, 2010 08:35 AM Keryx Biopharma (KERX) Presents Promising Data for KRX-0401 in Patients with CLL and HL

Sep 29, 2010 08:39 AM Keryx Biopharma (KERX) Initiates Long-Term Phase 3 of Zerenex

Jul 14, 2010 11:02 AM Keryx (KERX) Confirms Orphan Drug Designation for perifosine

Jun 29, 2010 09:02 AM Keryx Biopharma (KERX) Presents Data from P-CAP Versus CAP Phase III

Jun 29, 2010 07:33 AM Aeterna Zentaris (AEZS) Receives Positive SA from EMA for Perifosine Phase 3

Jun 8, 2010 09:05 AM Keryx Biopharma (KERX) Updates on KRX-0401 in Combo with Xeloda Phase II, Opens Phase III

Jun 7, 2010 09:49 AM Keryx Biopharma (KERX) Presented Data from KRX-0401 Phase 1 at ASCO, Shows Positive Safety and Tolerability Early

May 6, 2010 10:39 AM Keryx Biopharma (KERX) Initiates Zerenex Phase 3

Apr 15, 2010 08:50 AM Keryx Biopharma (KERX) Updates on Zerenex Hyperphosphatemia Treatment

Apr 8, 2010 08:39 AM Keryx Biopharma (KERX) Initiates Phase 3 Registration of KRX-0401 (AEZS)

Apr 5, 2010 08:51 AM Æterna Zentaris (AEZS) Partner Keryx Biopharma (KERX) Gets U.S. FDA Fast Track Designation for Perifosine

Apr 5, 2010 08:33 AM Keryx Biopharma (KERX) Receives FDA Fast Track for KRX-0401 (Perifosine)

Feb 3, 2010 08:39 AM Keryx Biopharma (KERX) Reaches Agreement with FDA Regarding SPA on Design of Phase 3 Trial for KRX-0401

Jan 29, 2010 08:57 AM Æterna Zentaris (AEZS) and Partner Keryx Biopharma (KERX) Report on Phase 2 of Perifosine Waldenstrom's Macroglobulinemia Treatment

Jan 25, 2010 08:52 AM Keryx Biopharma (KERX) Updates on KRX-401 PI3K/Akt Pathway Inhibitor for Cancer

Jan 5, 2010 08:44 AM Keryx Biopharma (KERX) and U.S. FDA Reach Agreement Regarding a SPA for Zerenex Phase 3 Design

Dec 16, 2009 08:47 AM AEterna Zentaris (AEZ) and Keryx BioPharma (KERX) Initiate KRX-0401 Phase 3

Nov 11, 2009 08:58 AM AEterna Zentaris (AEZS) Reports That Perifosine Partner Keryx Biopharma (KERX) Will Prersent Data from Phase 1/2 at 51st ASH Meeting

Nov 9, 2009 09:04 AM AEterna Zentaris (AEZS) Announces Publication of PI3K/Akt Article in Journal of Urology

Oct 8, 2009 09:07 AM Keryx Bio (KERX) Announces Perifosine Phase 2 for Chronic and Small Lymphocytic Leukemia

Sep 29, 2009 08:36 AM AEterna Zentaris (AEZS) Partner, Keryx (KERX), Presented Updated Phase 2 Data on Perifosine (KRX-0401) for the Treatment of Advanced Metastatic Renal Cell Carcinoma

Sep 23, 2009 08:51 AM Keryx (KERX) Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex

Sep 16, 2009 10:09 AM AEterna Zentaris' (AEZS) Partner, Keryx Biopharma, Receives FDA Orphan-Drug Designation for Perifosine

Sep 14, 2009 08:38 AM Keryx Biopharmaceuticals' (KERX) Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cance

Aug 31, 2009 12:28 PM Keryx Biopharmaceuticals (KERX) Files $40M Shelf Offering

Aug 3, 2009 09:14 AM Keryx Biopharma (KERX) Reaches Agreement with FDA on SPA for Phase 3 Trial of KRX-0401

Mar 5, 2009 10:03 AM Keryx Biopharma (KERX) Fails to Regain Compliance with Nasdaq Rules; to Be Delisted March 12 Unless Appealed

Sep 26, 2007 07:20 AM Keryx Biophama (KERX) Enters Licensing Agreement with Japan Tobacco and Torii Pharmaceutical